Eric Rubin, M.D., has served as a member of our board of directors since April 2026. He brings more than 35 years of experience in cancer drug development across academic and industry settings.
Most recently, Rubin served as senior vice president of global clinical oncology at Merck, where he held multiple senior leadership roles during his tenure. He led the initial development of KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States, and contributed to establishing its use across multiple cancer types.
Earlier in his career, Rubin was a faculty member at Dana-Farber Cancer Institute and later served as director of the Investigational Therapeutics Division at Rutgers Cancer Institute of New Jersey, where his research focused on oncology translational science. He has authored more than 100 peer-reviewed publications and has served on numerous national research and policy committees, including study sections for the National Cancer Institute and American Cancer Society, as well as program committees for the American Association for Cancer Research and the American Society of Clinical Oncology.
Rubin holds a B.S. in mathematics and biology from Tulane University and an M.D. from the University of South Florida.